| 词条 | Denileukin diftitox |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 477002950 | IUPAC_name = Diphtheria toxin-Interleukin-2 fusion protein | image = | tradename = Ontak | Drugs.com = {{drugs.com|monograph|denileukin_diftitox}} | MedlinePlus = a611024 | pregnancy_AU = | pregnancy_US = C | pregnancy_category = | legal_AU = | legal_UK = | legal_US = Rx-only | legal_status = | routes_of_administration = Intravenous | bioavailability = | protein_bound = | metabolism = | elimination_half-life = 70-80 min | excretion = | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 173146-27-5 | ATC_prefix = L01 | ATC_suffix = XX29 | ATC_supplemental = | PubChem = | IUPHAR_ligand = 7044 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00004 | UNII_Ref = {{fdacite|changed|FDA}} | UNII = 25E79B5CTM | ChEMBL_Ref = {{ebicite|changed|EBI}} | ChEMBL = 1201550 | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | C=2560 | H=4042 | N=678 | O=799 | S=17 | molecular_weight = 57647.3 g/mol }} Denileukin difitox (trade name Ontak) was an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors[1] and introduce the diphtheria toxin into cells that express those receptors, killing the cells. In some Leukemias and Lymphomas malignant cells express these receptors, so denileukin diftitox can target these. In 1999 Ontak was approved by the U.S. Food and Drug Administration (FDA) for treatment of Cutaneous T-cell lymphoma (CTCL).[2] There is some evidence tying it to vision loss and in 2006 the FDA added a black box warning to the drug's label.[2] In 2014 marketing of Ontak was discontinued in the US.[3] References1. ^{{cite journal |author=Turturro F |title=Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders |journal=Expert Rev Anticancer Ther |volume=7 |issue=1 |pages=11–7 |year=2007 |pmid=17187516 |doi=10.1586/14737140.7.1.11}} 2. ^1 FDA Page Last Updated: May 11, 2009 Changes in the Ontak (denileukin diftitiox) Package Insert to Include a Description of Ophthalmologic Adverse Events 3. ^{{cite web|title=FDA Drug Shortages|url=https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Denileukin+Diftitox+%28Ontak%29+Injection&st=d&tab=tabs-2|publisher=FDA|accessdate=3 July 2017|date=31 January 2014}} External links
2 : Antineoplastic drugs|Diphtheria |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。